The Start Up Fund and The Development Fund are Open for Investment
For more than 30 years, Oxford Technology has specialised in investing in start-up and early stage technology companies based near Oxford. Our 12th fund is still open for investment and is doing very well. The current results are shown below. Very detailed information on each of our investments and the progress of the funds can be found in our Quarterly Report.
At 10am on the first Thursday of every month, OTM organises presentations at which some of its investee companies pitch to investors. If you would like an invite to the next event on Thursday 3rd December, please enter your name at https://forms.gle/EcAY8z9Z1nY9ZRTE6.
Please be aware, that in order to make an investment, investors need to self-certify as a 'sophisticated investor' or a 'high net worth individual'. The definitions of these terms can be found here.
On Thursday 3rd December, four companies seeking additional EIS investment will make 10 minute presentations:
In February 2020, PolyCAT developed a prototype antiviral coating based on its existing technology platform. It seems that the way that the antimicrobial compound is presented on the surface of the treated materials is particularly good at deactivating viruses compared to competing technologies. The proprietary silver impregnated fabric conforms to ISO-18184:2019 (the internationally recognised standard for efficacy of antiviral fabrics) achieving an 'excellent' rating on all tests. Recognising this, the company signed on an international sales and marketing team to push this and other PolyCAT technologies to a wider audience. The antiviral material is down to the final three at 2 major household brand names, and in advanced trials at 3 others. All these opportunities represent long term technology goals for these potential customers which will outlast the immediate Covid-19 crisis.
PolyCAT has also started a major funded project with the US DoD/UK MoD evaluating another technology designed on the same platform. The company expects to grow significantly in 2021, and has started an EIS-eligible Series A fundraising round for £1m to accelerate this growth.
Etcembly is seeking to create a machine learning platform, EMLy (Etcembly Machine Learning) that contains a database of the human T cell repertoire of TCRs (T Cell Receptors) to interpret the immune system in the context of health and disease. Etcembly brings transformative acceleration to immunotherapy and vaccine design. Should there be a future pandemic outbreak, Etcembly will be able to design a candidate vaccine within days of the viral sequence being known. Etcembly started in January 2020 and has made excellent progress forging numerous partnerships with the National Cancer Centre Singapore, Bristol Myers Squibb, Parker Institute of Immunotherapy and Tessa Therapeutics, Imperial College and Great Ormond Street Hospital. EMLy now stores more than 300M TCR sequences in its database and this number will exceed a billion by the end of this year- a significant milestone as this will have captured the natural diversity of the human T cell repertoire within an individual.
During November, Etcembly has raised £280,000 at £1.58 per share which included £70,000 from OT(S)EIS. They are aiming to fill this round to £500,000 from additional investors. The funds will be used to hire talent to bring EMLy to market ready for partnering and licensing deals.
GripAble is developing an ecosystem of proprietary sensor-based devices and an engaging software and data platform, providing remote physical assessment and therapy. The system allows much of the therapy that now takes place in hospitals to be performed by the patient at-home, while still under therapist guidance. The first product is a digital handgrip device that connects wirelessly to GripAble’s mobile software app allowing patients with hand, wrist and arm impairment to complete objective assessments and engaging therapy games. A study at Imperial showed an eightfold increase in exercise among patients given the opportunity to use the device, with example case studies emerging of individuals achieving fourfold increases in strength after sustained use. There has been significant pre-launch sales traction (>400 systems deployed) and scalable manufacturing has been achieved. GripAble is raising a £1.5m round, £1.2m of which has already been committed, at a pre-money valuation of £9.25m.
SIME is a Clinical AI company applying medical excellence, proprietary AI and data science to deliver rapid respiratory intensive care diagnostics for acute unmet needs. The Company's clinically proven technology enables early intervention in life-threatening diseases - saving lives, improving outcomes and reducing costs. The first product to market, a breakthrough diagnostic test clinically proven to predict neonatal respiratory distress at birth, will be marketed to Neonatal Intensive Care Units in Europe, US, China and Latin America. The Company has pioneer installations in key markets (Copenhagen, London, Xi'an, Los Angeles), is protected by an extensive IP portfolio and has a world class management and scientific team.
SIME is currently fundraising to reach CE Mark and first milestone-based revenue in 2021 (signed commercial agreements in China and Latin America). SIME is raising £1.5m of which £500,000 will be as an advance subscription agreement at a 20% discount to the price of the balance of the £1.5m. £200,000 of this has already been subscribed.
Following the presentations, there will be a musical interlude with pianist Anita D'Attellis giving a live performance of Schubert Impromptu, op. 90, no. 3. During this interlude, listeners may submit questions to the presenters. After the interlude, the presenters will then answer at least some of these questions. Obviously it will be possible for any investor to follow up directly with any of the presenters to have further discussions.
We hope you can join us virtually on Thursday 3rd December. Please enter your name at https://forms.gle/EcAY8z9Z1nY9ZRTE6 and we will email you a link to join the meeting. Please let us know if you have any questions.
Oxford Technology hosts these investor presentations on the first Thursday of every month, free to subscribers to OT(S)EIS, and initially free to everyone.
To receive our Quarterly Reports as they are published please subscribe here: